AuriGen Medical is an Irish electrophysiology and structural heart company committed to transforming the management of persistent atrial fibrillation by developing the first cardiac implant to treat both the stroke and arrhythmia risk associated with this devastating condition. Everyday millions of patients suffer with atrial fibrillation, a condition characterized by an irregular heartbeat or arrhythmia which can lead to stroke, dementia, heart failure and death. Unfortunately for the majority of patients with persistent disease, the current treatment options are routinely ineffective. AuriGen Medical is developing the next generation of left atrial appendage implant to simultaneously address both the stroke and arrhythmia risk. The AuriGen technology is quick and intuitive to implant and incorporates biophotonic sensors for real time confirmation of procedural success, without the need for complex mapping. Our team are supported by strong international clinical and commercial advisory teams. AuriGen Medical have conducted successful acute and chronic pre-clinical studies in IMMR Paris, filed 4 patents and ranked 1st across Europe in the Horizon 2020 FTI and SME instruments securing over $7 million in non-dilutive funding. This funding will allow the company to prepare for first in human studies in 2020. We are AuriGen Medical and we are committed to transforming the future for all patients suffering with atrial fibrillation.
